The growth of the cancer vaccine market is expected to be mainly driven by increasing incidence, rising awareness and access to treatment, and the emergence of novel therapies such as OSE2101 (OSE Immunotherapeutic), Intismeran autogene (Merck/Moderna Therapeutics), CYLEMBIO (IO102-IO103) IO Biotech), Galinpepimut S (SELLAS Life Sciences), BNT113 (BioNTech), RP2 (Replimune), and others.. 癌症疫苗市场的增长预计将主要由发病率上升、治疗意识和可及性提高，以及新型疗法的涌现所驱动，例如 OSE2101（OSE Immunotherapeutic）、Intismeran autogene（默克/Moderna Therapeutics）、CYLEMBIO（IO102-IO103，IO Biotech）、Galinpepimut S（SELLAS Life Sciences）、BNT113（BioNTech）、RP2（Replimune）等。LAS VEGAS 拉斯维加斯, ，Sept. 21, 2026 2026年9月21日/PRNewswire/ -- DelveInsight's Cancer Vaccines Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Lung Cancer (NSCLC), Bladder Cancer, Prostate Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Cervical Cancer, and Other Solid Tumors. /美通社/ -- DelveInsight发布的《癌症疫苗市场规模、目标人群、竞争格局与市场预测》报告，全面剖析了当前的治疗实践及可覆盖的患者人群，涵盖黑色素瘤、肺癌（非小细胞肺癌）、膀胱癌、前列腺癌、乳腺癌、胰腺癌、头颈癌、宫颈癌及其他实体瘤等主要适应症。The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging cancer vaccines, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).. 所选适应症基于已获批的疗法和正在进行的研发管线活动。该报告还提供了对新兴癌症疫苗、各疗法的市场份额以及2022年至2036年当前和预测的市场规模的见解，并按主要市场（美国、欧盟四国、英国和日本）进行细分。Key Takeaways from the Cancer Vaccines Market Report 癌症疫苗市场报告的关键要点The cancer therapeutic vaccines market size was found to be 癌症治疗性疫苗市场规模被发现为~USD 335 million 约3.35亿美元in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025. 2025年，在主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）。The United States accounted for the largest cancer vaccinemarket size of the total market size in the 7MM in 2025, i.e., 2025年，美国在七大主要市场（7MM）中占据了最大的癌症疫苗市场份额，即87% 87%compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 与包括欧盟四大国（德国、法国、意大利和西班牙）、英国和日本在内的其他主要市场相比。The report provides the total potential number of patients in the indications, such as 该报告提供了各适应症中潜在患者总数，例如Melanoma, Lung Cancer (NSCLC), Bladder Cancer, Prostate Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Cervical Cancer, and Other Solid Tumors 黑色素瘤、肺癌（非小细胞肺癌）、膀胱癌、前列腺癌、乳腺癌、胰腺癌、头颈癌、宫颈癌及其他实体瘤. 。In the 7MM, total cases across selected indications for cancer therapeutic vaccines were highest for prostate cancer, at approximately 在7MM中，选定癌症治疗性疫苗适应症的总病例数以前列腺癌为最高，约为2.8 million 280万cases in 2025, and are projected to increase by 2036. 2025年的病例数，并预计到2036年将增加。Leading companies developing cancer vaccines include 开发癌症疫苗的领先企业包括OSE Immunotherapeutic, Moderna Therapeutics, Merck, CG Oncology, Os Therapies, Northwest Biotherapeutics, Advent Bioservices, Greenwich Lifesciences, Tuhura Biosciences, Genelux Corporation, Briacell Therapeutics, Oncotherapy Science, Shionogi, Transcode Therapeutics, CanariaBio, Candel Therapeutics, Sellas Life Sciences, BioNTech, Aston Sciences, IO Biotech, . OSE免疫治疗公司、莫德纳治疗公司、默克公司、CG肿瘤公司、Os治疗公司、西北生物治疗公司、Advent生物服务公司、格林威治生命科学公司、Tuhura生物科学公司、Genelux公司、Briacell治疗公司、Oncotherapy Science公司、盐野义制药公司、Transcode治疗公司、CanariaBio公司、Candel治疗公司、Sellas生命科学公司、BioNTech公司、Aston Sciences公司、IO Biotech公司。and others. 等等。Some of the key cancer vaccinesin clinical trials include 临床试验中的一些关键癌症疫苗包括OSE-2101 (TEDOPI), Intismeran Autogene (MRNA-4157/V940), Cretostimogene Grenadenorepvec, OST-HER2, DCVAX, GLSI-100, IFX-HU2.0 (IFX-2.0), Olvimulogene Nanivacirepvec (OLVI-VEC), SV-BR-1-GM (BRIA-IMT), S-588410, SEVIPROTIMUT L, Oregovomab, Aglatimagene Besadenovec (CAN-2409), Galinpepimut-S (GPS), BNT113, AST-301, AST-201, IO102-IO103, . OSE-2101（TEDOPI）、Intismeran Autogene（MRNA-4157/V940）、Cretostimogene Grenadenorepvec、OST-HER2、DCVAX、GLSI-100、IFX-HU2.0（IFX-2.0）、Olvimulogene Nanivacirepvec（OLVI-VEC）、SV-BR-1-GM（BRIA-IMT）、S-588410、SEVIPROTIMUT L、Oregovomab、Aglatimagene Besadenovec（CAN-2409）、Galinpepimut-S（GPS）、BNT113、AST-301、AST-201、IO102-IO103and others. 以及其他。Discover the latest studies on cancer vaccines 2026 @ 探索2026年癌症疫苗的最新研究 @https://www.delveinsight.com/report-store/cancer-vaccines-market https://www.delveinsight.com/report-store/cancer-vaccines-marketKey Factors Driving the Cancer Vaccines Market 推动癌症疫苗市场发展的关键因素Rising Global Cancer Burden: 全球癌症负担日益加重：The increasing incidence of cancer worldwide is creating a greater need for innovative preventive and therapeutic treatment approaches. The growing patient population is expanding the potential demand for cancer vaccines across multiple cancer types. 全球癌症发病率的不断上升，使得对创新预防和治疗手段的需求日益迫切。患者群体的不断扩大，也推动了多种癌症类型对癌症疫苗的潜在需求增长。Advancements in Cancer Immunotherapy: 癌症免疫疗法的进展：Rapid progress in immuno-oncology is improving understanding of how the immune system can recognize and attack tumor cells. These advances are supporting the development of therapeutic cancer vaccines designed to generate targeted anti-tumor immune responses. 免疫肿瘤学的快速进展正在提升我们对免疫系统如何识别和攻击肿瘤细胞的理解。这些进步正支持着治疗性癌症疫苗的开发，旨在产生针对性的抗肿瘤免疫反应。Growth of Personalized Cancer Vaccines: 个性化癌症疫苗的增长：Advances in genomic sequencing and biomarker identification are enabling the development of personalized vaccines based on individual tumor mutations. Neoantigen-based vaccine approaches are attracting significant interest because of their potential to provide highly targeted treatment. 基因组测序和生物标志物识别的进展，使得基于个体肿瘤突变的个性化疫苗的开发成为可能。基于新抗原的疫苗方法因其提供高度靶向治疗的潜力而受到广泛关注。Increasing Adoption of mRNA Vaccine Technology: mRNA疫苗技术的日益普及：The success of mRNA-based vaccine platforms has accelerated investment and technological development in cancer vaccine research. mRNA platforms offer flexible manufacturing and can potentially encode multiple tumor-specific antigens within a single vaccine. 基于mRNA的疫苗平台的成功加速了癌症疫苗研究领域的投资和技术发展。mRNA平台具有灵活的生产制造优势，并有可能在单一疫苗中编码多种肿瘤特异性抗原。Expansion of Clinical Trials and Product Pipelines: 临床试验与产品管线的扩展：Pharmaceutical and biotechnology companies are increasing investments in clinical-stage cancer vaccine candidates targeting melanoma, lung cancer, prostate cancer, pancreatic cancer, and other malignancies. A growing pipeline of candidates such as 制药和生物技术公司正在增加对针对黑色素瘤、肺癌、前列腺癌、胰腺癌及其他恶性肿瘤的临床阶段癌症疫苗候选药物的投资。日益增长的候选药物管线，例如OSE-2101 OSE-2101(TEDOPI; OSE Immunotherapeutic), (TEDOPI；OSE Immunotherapeutic)，Intismeran Autogene Intismeran Autogene(MRNA-4157/V940; Moderna Therapeutics and Merck), （MRNA-4157/V940；Moderna Therapeutics 和默克公司）Cretostimogene Grenadenorepvec 克雷托刺激基因 Grenadenorepvec(CG Oncology), (CG肿瘤学),OST-HER2 OST-HER2(Os Therapies), and others is supporting market expansion and increasing opportunities for commercialization. （OS疗法）等正在支持市场扩张，并增加商业化机会。Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that prostate cancer is expected to account for ~18% of the cancer therapeutic vaccines market in 2036. Melanoma, breast cancer, NSCLC, and NMIBC are among the fastest-growing segments during 2031–2036. DelveInsight 预测与分析功能负责人 Sadaf Javed 表示，预计到 2036 年，前列腺癌将占癌症治疗性疫苗市场约 18% 的份额。在 2031 年至 2036 年期间，黑色素瘤、乳腺癌、非小细胞肺癌（NSCLC）和非肌层浸润性膀胱癌（NMIBC）是增长最快的细分市场。Cancer Vaccines Market Analysis 癌症疫苗市场分析Cancer vaccines are progressing from an experimental immunotherapy approach toward a more established clinical opportunity, driven by advances in tumor sequencing, neoantigen discovery, mRNA-based platforms, and computational technologies for antigen prediction. 在肿瘤测序、新抗原发现、基于mRNA的平台以及抗原预测计算技术的推动下，癌症疫苗正从一种实验性免疫疗法逐步发展为更为成熟的临床机遇。Despite these advances, the market continues to face a substantial gap between encouraging immunogenicity and the ability to consistently translate immune responses into meaningful late-stage clinical outcomes. 尽管取得了这些进展，市场仍然面临着一个巨大的差距：一方面免疫原性令人鼓舞，另一方面却难以始终如一地将免疫反应转化为具有临床意义的后期阶段成果。Melanoma 黑色素瘤has emerged as a key benchmark for immune-based therapeutic development due to its high immunogenicity, established use of immune checkpoint inhibitors, and the availability of validated oncolytic and immunotherapy approaches. 由于其高免疫原性、免疫检查点抑制剂的成熟应用，以及经过验证的溶瘤病毒和免疫治疗手段的可及性，它已成为基于免疫的治疗开发的关键基准。At the same time, cancer vaccine development is expanding into challenging solid tumors, including Non-small Cell Lung Cancer (NSCLC), pancreatic cancer, ovarian cancer, prostate cancer, and other tumor types, thereby broadening the potential addressable patient population. 与此同时，癌症疫苗的研发正拓展至具有挑战性的实体瘤领域，包括非小细胞肺癌（NSCLC）、胰腺癌、卵巢癌、前列腺癌以及其他肿瘤类型，从而扩大了潜在的可惠及患者群体。Although the approved therapeutic landscape remains relatively limited, it is gradually expanding beyond the pioneering cancer vaccine 尽管已获批的治疗格局仍然相对有限，但正逐步超越首创的癌症疫苗，不断拓展。Sipuleucel-T (PROVENGE) 西普鲁仑-T（PROVENGE）. 。Sipuleucel-T continues to represent the established therapeutic cancer vaccine and is approved in the US for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its demonstrated survival benefit provides clinical validation for the potential of vaccine-based immunotherapy.. Sipuleucel-T 仍然是已确立的治疗性癌症疫苗的代表，在美国获准用于治疗无症状或症状轻微的转移性去势抵抗性前列腺癌（mCRPC）。其证实的生存获益为基于疫苗的免疫疗法的潜力提供了临床验证。The broader immunotherapy landscape is also receiving regulatory validation through the development of oncolytic viral therapies. 通过溶瘤病毒疗法的发展，更广泛的免疫治疗领域也正获得监管机构的认可。Talimogene laherparepvec (IMLYGIC) and Teserpaturev/G47Δ (DELYTACT) 塔利莫根拉赫帕雷普韦克（IMLYGIC）和特瑟帕图雷夫/G47Δ（DELYTACT）established commercial precedents in melanoma and malignant glioma, respectively. 分别在黑色素瘤和恶性胶质瘤领域建立了商业化先例。In addition, 此外，Telomelysin (OBP-301/suratadenoturev) 端粒酶溶素（OBP-301/苏拉地诺图雷夫）received full approval in Japan in 2026 for esophageal cancer. 2026年在日本获得食管癌的全面批准。More recently, 最近，Vusolimogene oderparepvec (TUDRIQEV) Vusolimogene oderparepvec（TUDRIQEV）received FDA accelerated approval in August 2026 in combination with nivolumab for PD-1-refractory advanced melanoma, further highlighting the potential of localized immune activation and combination-based treatment strategies. 于2026年8月获得美国食品药品监督管理局（FDA）加速批准，与纳武利尤单抗联合用于治疗对PD-1抑制剂耐药的晚期黑色素瘤，进一步凸显了局部免疫激活和基于联合治疗策略的潜力。The field is increasingly moving toward personalized neoantigen vaccines, supported by advances in tumor sequencing, artificial intelligence-driven antigen prediction, mRNA technologies, and computational platforms. 在肿瘤测序、人工智能驱动的抗原预测、mRNA技术以及计算平台进步的推动下，该领域正日益向个性化新抗原疫苗方向发展。These technologies enable the development of vaccine candidates tailored to the unique mutational characteristics and antigenic profiles of individual tumors, supporting a more personalized approach to cancer immunotherapy. 这些技术使得能够开发出针对个体肿瘤独特突变特征和抗原谱的候选疫苗，从而支持更加个性化的癌症免疫治疗方法。Combination therapy has increasingly become a central development strategy, with cancer vaccines frequently being evaluated alongside PD-1/PD-L1 inhibitors and other immune-modulating agents. 联合疗法日益成为核心开发策略，癌症疫苗常与PD-1/PD-L1抑制剂及其他免疫调节剂一同接受评估。These combinations are intended to strengthen vaccine-induced T-cell responses while addressing the immunosuppressive tumor microenvironment. As a result, cancer vaccines are increasingly being positioned as immune-priming platforms or therapeutic backbones rather than as standalone treatments. 这些联合方案旨在增强疫苗诱导的T细胞反应，同时应对免疫抑制性的肿瘤微环境。因此，癌症疫苗正日益被定位为免疫启动平台或治疗基石，而非作为单一疗法使用。Earlier-stage disease and minimal residual disease settings represent another significant opportunity for cancer therapeutic vaccines. Patients with lower tumor burden may provide a more favorable setting for vaccine-induced immune control compared with those with heavily advanced or pretreated disease.. 早期疾病和微小残留病灶状态为癌症治疗性疫苗提供了另一个重要机遇。与肿瘤负荷较重或经多线预处理的晚期患者相比，肿瘤负荷较低的患者可能为疫苗诱导的免疫控制提供更有利的环境。Accordingly, adjuvant, perioperative, and Measurable Residual Disease (MRD)-directed strategies may offer greater opportunities to demonstrate recurrence-free and overall survival benefits. 因此，辅助治疗、围手术期治疗以及针对可测量残留病灶（MRD）的策略可能在展示无复发生存和总生存获益方面提供更大的机会。The cancer therapeutic vaccines pipeline is highly diversified, encompassing a broad range of late-stage and innovative candidates being developed by leading companies and research organizations. 癌症治疗性疫苗的研发管线高度多元化，涵盖了由领先企业和研究机构开发的众多后期阶段及创新候选产品。Key candidates include 主要候选人包括OSE2101, Intismeran autogene, IO102-IO103 (CYLEMBIO), GLSI-100, OST-HER2, DCVax, Aglatimagene besadenovec (CAN-2409), Cretostimogene grenadenorepvec, Olvi-Vec, Seviprotimut L, Oregovomab, S-588410, Galinpepimut S, BNT113, AST-301, AST-201 OSE2101、Intismeran autogene、IO102-IO103（CYLEMBIO）、GLSI-100、OST-HER2、DCVax、Aglatimagene besadenovec（CAN-2409）、Cretostimogene grenadenorepvec、Olvi-Vec、Seviprotimut L、Oregovomab、S-588410、Galinpepimut S、BNT113、AST-301、AST-201, and other emerging therapeutic vaccine programs. ，以及其他新兴的治疗性疫苗项目。Learn more about the FDA approved cancer vaccines@ 了解更多关于FDA批准的癌症疫苗的信息 @Approved Cancer Vaccines 2026 2026年获批的癌症疫苗Cancer Vaccines Competitive Landscape 癌症疫苗竞争格局Some of the cancer therapeutic vaccines under development include 正在开发的一些癌症治疗性疫苗包括OSE-2101 OSE-2101(TEDOPI; OSE Immunotherapeutic), (TEDOPI；OSE免疫治疗公司)Intismeran Autogene Intismeran Autogene(MRNA-4157/V940; Moderna Therapeutics and Merck), （MRNA-4157/V940；Moderna Therapeutics 和默克公司）Cretostimogene Grenadenorepvec 克雷托刺激基因格雷纳多内普维克(CG Oncology), (CG Oncology),OST-HER2 OST-HER2(Os Therapies), （操作系统疗法）DCVAX DCVAX(Northwest Biotherapeutics and Advent Bioservices), （西北生物治疗公司和Advent Bioservices公司）GLSI-100 GLSI-100(Greenwich Lifesciences), （格林威治生命科学公司）IFX-HU2.0 IFX-HU2.0(IFX-2.0; Tuhura Biosciences), (IFX-2.0；Tuhura Biosciences)，Olvimulogene Nanivacirepvec 奥维穆洛基因 纳米瓦西雷普维克(OLVI-VEC; Genelux Corporation), (OLVI-VEC；Genelux公司),SV-BR-1-GM SV-BR-1-GM(BRIA-IMT; Briacell Therapeutics), (BRIA-IMT；Briacell Therapeutics)，S-588410 S-588410(Oncotherapy Science/Shionogi), （Oncotherapy Science/盐野义）SEVIPROTIMUT L 左旋塞维普罗替穆特(Transcode Therapeutics), (Transcode Therapeutics),Oregovomab 奥雷戈单抗(CanariaBio), （CanariaBio）Aglatimagene Besadenovec 阿格拉蒂马基因贝萨多诺韦克(CAN-2409; Candel Therapeutics), (CAN-2409；Candel Therapeutics)，Galinpepimut-S 加利肽普特-S(GPS; Sellas Life Sciences), (GPS；Sellas Life Sciences)，BNT113 BNT113(BioNTech), （BioNTech）AST-301 AST-301(Aston Sciences), （阿斯顿科学公司）AST-201 AST-201(Aston Sciences), （阿斯顿科学公司）IO102-IO103 IO102-IO103(IO Biotech), and others. (IO Biotech) 等。OSE Immunotherapeutic's OSE-2101 OSE免疫治疗公司的OSE-2101is a novel T-cell epitope-based cancer vaccine targeting five tumor-associated antigens. It is designed as an off-the-shelf immunotherapy that activates and differentiates tumor-specific T-cell responses and promotes the expansion of tumor-reactive lymphocytes in HLA-A2-positive cancer patients. According to ClinicalTrials.gov, the Phase III ATALANTE-1 trial evaluating OSE-2101 in patients with advanced or metastatic NSCLC was terminated prematurely due to the COVID-19 pandemic. 是一种基于新型T细胞表位的癌症疫苗，靶向五种肿瘤相关抗原。它被设计为一种现成的免疫疗法，旨在激活和分化肿瘤特异性T细胞反应，并促进HLA-A2阳性癌症患者体内肿瘤反应性淋巴细胞的扩增。根据ClinicalTrials.gov的信息，评估OSE-2101在晚期或转移性非小细胞肺癌（NSCLC）患者中疗效的III期ATALANTE-1试验因新冠疫情而提前终止。However, encouraging overall survival outcomes observed in patients with secondary resistance to immune checkpoint inhibitors (ICIs) supported continued clinical development.. 然而，在对免疫检查点抑制剂（ICIs）产生继发性耐药的患者中观察到的令人鼓舞的总生存期结果，支持了进一步的临床开发。OSE-2101 is currently being evaluated in OSE-2101 目前正在接受评估ARTEMIA 卤虫, a new registrational Phase III study comparing the therapy with docetaxel in HLA-A2-positive patients with metastatic NSCLC who have developed secondary resistance to ICIs. Additional Phase II programs include ，一项新的注册性III期研究，在继发免疫检查点抑制剂（ICI）耐药的HLA-A2阳性转移性非小细胞肺癌（NSCLC）患者中，比较该疗法与多西他赛的疗效。其他II期项目包括CombiTED CombiTED, which is evaluating OSE-2101 in combination with nivolumab (OPDIVO) in NSCLC; ，正在评估 OSE-2101 与纳武利尤单抗（OPDIVO）联合用于非小细胞肺癌（NSCLC）的治疗；TEDOPaM TEDOPaM, assessing the therapy with FOLFIRI in pancreatic cancer; and ，评估FOLFIRI方案在胰腺癌中的治疗作用；以及TEDOVA TEDOVA, investigating OSE-2101 alone or in combination with pembrolizumab (KEYTRUDA) in ovarian cancer. The U.S. FDA has granted ，研究 OSE-2101 单药或联合帕博利珠单抗（KEYTRUDA）治疗卵巢癌。美国食品药品监督管理局已授予Orphan Drug Designation (ODD) 孤儿药资格认定（ODD）to OSE-2101 for the treatment of NSCLC. 用于 OSE-2101 治疗非小细胞肺癌（NSCLC）。Moderna Therapeutics and Merck's Intismeran autogene 莫德纳治疗公司与默沙东的Intismeran autogeneis an investigational, personalized mRNA-based Individualized Neoantigen Therapy (INT) that incorporates synthetic mRNA encoding up to 34 patient-specific neoantigens identified from an individual tumor. The therapy is designed to generate a targeted antitumor immune response by stimulating and expanding neoantigen-specific T cells according to the unique mutational profile of each patient's tumor. 是一种在研的、基于mRNA的个性化新抗原疗法（INT），其包含编码多达34种从个体肿瘤中鉴定出的患者特异性新抗原的合成mRNA。该疗法旨在根据每位患者肿瘤的独特突变谱，刺激并扩增新抗原特异性T细胞，从而产生靶向抗肿瘤免疫反应。Merck and Moderna are advancing the intismeran autogene clinical development program across multiple tumor types and treatment settings, including ongoing Phase III studies in melanoma and NSCLC, as well as additional trials in other solid tumors and earlier-stage disease. In February 2023, the combination of intismeran autogene and pembrolizumab received . 默克公司和莫德纳公司正在推进intismeran autogene在多种肿瘤类型和治疗场景下的临床开发计划，包括正在进行的针对黑色素瘤和非小细胞肺癌（NSCLC）的III期研究，以及在其他实体瘤和更早阶段疾病中的额外试验。2023年2月，intismeran autogene与帕博利珠单抗的联合疗法获得了。FDA Breakthrough Therapy Designation FDA突破性疗法认定for the adjuvant treatment of patients with high-risk melanoma following complete surgical resection. In April 2023, intismeran autogene received 用于高危黑色素瘤患者完全手术切除后的辅助治疗。2023年4月，intismeran autogene获得PRIME Scheme Designation PRIME计划认定from the EMA for the adjuvant treatment of patients with high-risk Stage III/IV melanoma following complete resection. 来自欧洲药品管理局（EMA），用于完全切除后的高风险III/IV期黑色素瘤患者的辅助治疗。IO Biotech's IO102-IO103 IO Biotech 的 IO102-IO103is an investigational therapeutic cancer vaccine designed to target both tumor cells and immunosuppressive cells within the tumor microenvironment (TME). The therapy stimulates the activation and expansion of T cells directed against indoleamine 2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1)-expressing cells. 是一种研究性治疗性癌症疫苗，旨在靶向肿瘤微环境（TME）中的肿瘤细胞和免疫抑制细胞。该疗法可刺激针对表达吲哚胺2,3-双加氧酶（IDO）和/或程序性死亡配体1（PD-L1）的细胞的T细胞活化与扩增。Results from the pivotal Phase III . 关键性III期临床试验结果。IOB-013/KN-D18 trial (NCT05155254) IOB-013/KN-D18 试验（NCT05155254）in first-line advanced melanoma were presented at ESMO 2025. Although the combination of IO102-IO103 with pembrolizumab demonstrated a numerical improvement in progression-free survival (PFS), the primary PFS endpoint did not reach statistical significance. Following these findings, the company planned discussions with the FDA regarding the potential design of a new registrational Phase III study. 在2025年欧洲肿瘤内科学会（ESMO）年会上公布了IO102-IO103联合帕博利珠单抗用于一线治疗晚期黑色素瘤的研究结果。尽管该联合疗法在无进展生存期（PFS）方面显示出数值上的改善，但主要终点PFS未达到统计学显著性。基于这些结果，公司计划与美国食品药品监督管理局（FDA）就新的注册性III期临床试验的潜在设计进行讨论。The Phase II solid-tumor basket study . II期实体瘤篮子研究NCT05077709 NCT05077709has been completed, while 已完成，而NCT05280314 NCT05280314is evaluating IO102-IO103 in the neoadjuvant and adjuvant settings for patients with resectable melanoma and squamous cell carcinoma of the head and neck (SCCHN). 正在评估IO102-IO103在可切除黑色素瘤和头颈部鳞状细胞癌（SCCHN）患者新辅助和辅助治疗中的应用。Candel Therapeutics' CAN-2409 Candel Therapeutics 的 CAN-2409, also known as ，也称为aglatimagene besadenovec 阿格拉替马基因贝萨德诺韦克, is an investigational, off-the-shelf, replication-defective adenoviral therapy designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene directly to tumor cells and stimulate a systemic antitumor immune response. Candel is currently evaluating CAN-2409 in NSCLC, borderline-resectable pancreatic ductal adenocarcinoma (PDAC), and localized, non-metastatic prostate cancer. 是一种在研的、现成的、复制缺陷型腺病毒疗法，旨在将单纯疱疹病毒胸苷激酶（HSV-tk）基因直接递送至肿瘤细胞，并激发全身性抗肿瘤免疫反应。Candel 目前正在非小细胞肺癌（NSCLC）、临界可切除胰腺导管腺癌（PDAC）以及局限性、非转移性前列腺癌中评估 CAN-2409。In May 2026, the company reported new findings from extended follow-up of its randomized, double-blind, placebo-controlled pivotal Phase III trial of aglatimagene besadenovec in patients with intermediate- to high-risk localized prostate cancer. The results showed a consistent clinical benefit across multiple exploratory endpoints and further supported the positive topline findings initially reported in December 2024 following an additional 20 months of follow-up.. 2026年5月，公司报告了其针对中高危局限性前列腺癌患者开展的阿格拉蒂马金贝萨多诺韦（aglatimagene besadenovec）随机、双盲、安慰剂对照关键性III期试验的延长随访新发现。结果显示，在多个探索性终点上均观察到一致的临床获益，并进一步支持了此前于2024年12月公布的积极顶线结果，该结果基于额外20个月的随访数据。The anticipated launch of these emerging therapies are poised to transform the cancer vaccinesmarket landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cancer vaccinesmarket landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年内改变癌症疫苗市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计它们将重塑癌症疫苗市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。To know more about leading biopharmaceutical companies developing cancer vaccines, visit @ 如需了解更多关于开发癌症疫苗的领先生物制药公司的信息，请访问 @Cancer Vaccines Market 癌症疫苗市场Recent Developments in the Cancer Vaccines Market 癌症疫苗市场的最新发展In 在August 2026, Merck and Moderna 2026年8月，默克公司与莫德纳公司announced positive Phase III INTerpath-001 results, with intismeran autogene significantly improving recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus KEYTRUDA alone in resected melanoma. It marks the first positive Phase III readout for an individualized neoantigen and mRNA-based cancer therapy.. 宣布III期INTerpath-001研究取得阳性结果，与单独使用KEYTRUDA相比，intismeran autogene显著改善了切除后黑色素瘤患者的无复发生存期（RFS）和无远处转移生存期（DMFS）。这标志着个体化新抗原及mRNA癌症疗法首次获得阳性III期临床数据。In 在August 2026, 2026年8月，the US FDA granted accelerated approval to vusolimogene oderparepvec (TUDRIQEV) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma. 美国食品药品监督管理局（FDA）批准vusolimogene oderparepvec（TUDRIQEV）与纳武利尤单抗联合用于成人不可切除的晚期皮肤黑色素瘤。In 在August 2026, 2026年8月，Positive Phase III INTerpath-001 results in completely resected Stage IIB-IV melanoma were presented for Intismeran autogene. Intismeran autogene 在完全切除的 IIB-IV 期黑色素瘤患者中取得的阳性 III 期 INTerpath-001 研究结果已公布。In 在July 2026, 2026年7月，VCN-01 has FDA/EMA Orphan Drug and FDA Rare Pediatric Disease designations for retinoblastoma, with potential Priority Review Voucher eligibility if FDA approval is obtained by September 30, 2029. VCN-01 已获得美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）针对视网膜母细胞瘤的孤儿药认定，以及 FDA 的罕见儿科疾病认定；若能在 2029 年 9 月 30 日前获得 FDA 批准，则有资格获得优先审评券。In 在May 2026, 2026年5月，the US FDA granted Fast Track designation for the treatment of unresectable or metastatic cutaneous melanoma to DOC1021. 美国食品药品监督管理局（FDA）授予DOC1021用于治疗不可切除或转移性皮肤黑色素瘤的“快速通道”资格。In 在March 2026, Candel Therapeutics 2026年3月，Candel Therapeuticsis in an ongoing dialogue with the FDA in preparation for the anticipated submission of a BLA for aglatimagene besadenovec in prostate cancer in Q4 2026. 正与美国食品药品监督管理局（FDA）进行持续沟通，为预计于2026年第四季度提交阿格拉蒂马基因贝萨德诺韦克（aglatimagene besadenovec）用于治疗前列腺癌的生物制品许可申请（BLA）做准备。In 在January 2026, 2026年1月，the FDA granted Fast Track Designation (FTD) for HPV16-positive head and neck cancer to BNT113. 美国食品药品监督管理局（FDA）授予BNT113针对HPV16阳性头颈癌的快速通道认定（FTD）。Cancer Vaccines Epidemiology Segmentation 癌症疫苗流行病学细分The cancer vaccines market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. 癌症疫苗市场报告是一份全面且专业的分析，为2022年至2036年研究期间的主要市场提供深入的流行病学洞察。Approximately 10–20% 大约 10–20%of patients with melanoma develop metastatic disease, with the risk increasing substantially among patients with thicker, ulcerated, or regionally advanced tumors. 部分黑色素瘤患者会发展为转移性疾病，且在肿瘤较厚、溃疡或区域晚期患者中，风险显著增加。The cancer vaccines target patient pool is segmented into: 癌症疫苗的目标患者群体细分为：Total Eligible Patient Pool for Cancer Vaccines in Selected Indications 选定适应症中癌症疫苗的合格患者总池Total Cases of Selected Indications for Cancer Vaccines 癌症疫苗选定适应症的总病例数Total Treated Cases in Selected Indications for Cancer Vaccines 选定适应症中癌症疫苗的总治疗病例数Cancer Vaccines Report Metrics 癌症疫苗报告指标Details 详情Study Period 学习周期2022–2036 2022–2036Cancer Vaccines ReportCoverage 癌症疫苗报告覆盖范围7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] 7MM [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]Cancer Vaccines Market CAGR 癌症疫苗市场复合年增长率36% 36%Cancer Vaccines Market Size in 2025 2025年癌症疫苗市场规模USD 335 Million 3.35亿美元Key Cancer Vaccines Companies 主要癌症疫苗公司OSE Immunotherapeutic, Moderna Therapeutics, Merck, CG Oncology, Os Therapies, Northwest Biotherapeutics, Advent Bioservices, Greenwich Lifesciences, Tuhura Biosciences, Genelux Corporation, Briacell Therapeutics, Oncotherapy Science, Shionogi, Transcode Therapeutics, CanariaBio, Candel Therapeutics, Sellas Life Sciences, BioNTech, Aston Sciences, IO Biotech, Amgen, Daiichi Sankyo, Dendreon Pharmaceuticals, and others. OSE免疫治疗公司、Moderna Therapeutics、默克公司、CG Oncology、Os Therapies、Northwest Biotherapeutics、Advent Bioservices、Greenwich Lifesciences、Tuhura Biosciences、Genelux Corporation、Briacell Therapeutics、Oncotherapy Science、盐野义制药、Transcode Therapeutics、CanariaBio、Candel Therapeutics、Sellas Life Sciences、BioNTech、Aston Sciences、IO Biotech、安进、第一三共、Dendreon Pharmaceuticals，以及其他公司。KeyCancer Vaccines 关键癌症疫苗OSE-2101 (TEDOPI), Intismeran Autogene (MRNA-4157/V940), Cretostimogene Grenadenorepvec, OST-HER2, DCVAX, GLSI-100, IFX-HU2.0 (IFX-2.0), Olvimulogene Nanivacirepvec (OLVI-VEC), SV-BR-1-GM (BRIA-IMT), S-588410, SEVIPROTIMUT L, Oregovomab, Aglatimagene Besadenovec (CAN-2409), Galinpepimut-S (GPS), BNT113, AST-301, AST-201, IO102-IO103, IMLYGIC, DELYTACT, TUDRIQEV, PROVENGE, and others. OSE-2101（TEDOPI）、Intismeran Autogene（MRNA-4157/V940）、Cretostimogene Grenadenorepvec、OST-HER2、DCVAX、GLSI-100、IFX-HU2.0（IFX-2.0）、Olvimulogene Nanivacirepvec（OLVI-VEC）、SV-BR-1-GM（BRIA-IMT）、S-588410、SEVIPROTIMUT L、Oregovomab、Aglatimagene Besadenovec（CAN-2409）、Galinpepimut-S（GPS）、BNT113、AST-301、AST-201、IO102-IO103、IMLYGIC、DELYTACT、TUDRIQEV、PROVENGE 等。Scope of the 范围Cancer Vaccines 癌症疫苗Market Report 市场报告Cancer Vaccines Patient Population Forecast 癌症疫苗患者人群预测Cancer Vaccines Therapeutics Market Size 癌症疫苗治疗市场规模Cancer Vaccines Pipeline Analysis 癌症疫苗研发管线分析Cancer Vaccines Market Size and Trends 癌症疫苗市场规模与趋势Cancer Vaccines Market Opportunity 癌症疫苗市场机遇Cancer Vaccines Market Unmet Needs 癌症疫苗市场的未满足需求KOL's Views on Cancer Vaccines KOL对癌症疫苗的观点Cancer Vaccines Market Access and Reimbursement 癌症疫苗的市场准入与报销Download the report to understand the clinical development of cancer vaccines@ 下载报告以了解癌症疫苗的临床开发进展 @Cancer Vaccines Current Status 2026 2026年癌症疫苗现状Table of Contents 目录1 1Cancer Vaccines Market Key Insights 癌症疫苗市场关键洞察2 2Cancer Vaccines Market Report Introduction 癌症疫苗市场报告简介3 3Executive Summary of Cancer Therapeutic Vaccines 癌症治疗性疫苗执行摘要4 4Key Events 关键事件5 5Epidemiology and Market Forecast Methodology 流行病学与市场预测方法论6 6Cancer Therapeutic Vaccines Market Overview at a Glance 癌症治疗性疫苗市场概览6.1 6.1Clinical Landscape Analysis (by Molecule Type and Phase) 临床格局分析（按分子类型和阶段划分）6.2 6.2Market Share (%) Distribution by Indications of Cancer Therapeutic Vaccines in 2025 2025年癌症治疗性疫苗按适应症划分的市场份额（%）分布6.3 6.3Market Share (%) Distribution by Indications of Cancer Therapeutic Vaccines in 2036 2036年癌症治疗性疫苗按适应症划分的市场份额（%）分布7 7Cancer Therapeutic Vaccines: Background and Overview 癌症治疗性疫苗：背景与概述7.1 7.1Introduction 简介7.2 7.2History 历史7.3 7.3Mechanism 机制7.4 7.4Tumor Properties to Consider for Cancer Therapeutic Vaccines 癌症治疗性疫苗需考虑的肿瘤特性7.5 7.5Categories 分类7.6 7.6Advantages 优点7.7 7.7Limitations 局限性8 8Epidemiology and Patient Population of Cancer Therapeutic Vaccines in the 7MM 七大主要市场癌症治疗性疫苗的流行病学及患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale 假设与理由8.3 8.3Epidemiology Scenario in the 7MM 七大主要市场的流行病学情景8.3.1 8.3.1Total Cases of Selected Indications for Cancer Therapeutic Vaccines in the 7MM 七大主要市场中癌症治疗性疫苗选定适应症的总病例数8.3.2 8.3.2Indication-wise Eligible Cases for Cancer Therapeutic Vaccines in the 7MM 七大主要市场（7MM）中按适应症划分的癌症治疗性疫苗适用病例8.3.3 8.3.3Indication-wise Treated Cases for Cancer Therapeutic Vaccines in the 7MM 七大主要市场（7MM）中按适应症划分的癌症治疗性疫苗接种病例数9 9Marketed Therapies 上市疗法9.1 9.1Competitive Landscape of Marketed Therapies Related to Cancer Therapeutic Vaccines 癌症治疗性疫苗相关上市疗法的竞争格局9.2 9.2Talimogene laherparepvec (IMLYGIC): Amgen 塔利莫金·拉赫帕雷普韦克（IMLYGIC）：安进9.2.1 9.2.1Product Description 产品描述9.2.2 9.2.2Regulatory Milestones 监管里程碑9.2.3 9.2.3Other Developmental Activities 其他发展活动9.2.4 9.2.4Summary of Pivotal Trials 关键试验总结9.2.5 9.2.5Analyst View 分析师观点9.3 9.3Teserpaturev (DELYTACT): Daiichi Sankyo Teserpaturev（DELYTACT）：第一三共9.4 9.4Telomelysin (OBP-301/Suratadenoturev): Oncolys BioPharma 端粒溶解素（OBP-301/Suratadenoturev）：Oncolys BioPharma9.5 9.5Vusolimogene oderparepvec (TUDRIQEV): Replimune Vusolimogene oderparepvec（TUDRIQEV）：Replimune9.6 9.6Sipuleucel-T (PROVENGE): Dendreon Pharmaceuticals 西普鲁仑-T（PROVENGE）：Dendreon 制药公司10 10Emerging Therapies 新兴疗法10.1 10.1Competitive Landscape of Emerging Therapies Related to Cancer Therapeutic Vaccines 癌症治疗性疫苗相关新兴疗法的竞争格局10.2 10.2OSE-2101 (TEDOPI): OSE Immunotherapeutic OSE-2101（TEDOPI）：OSE免疫疗法公司10.2.1 10.2.1Product Description 产品描述10.2.2 10.2.2Regulatory Milestones 监管里程碑10.2.3 10.2.3Other Developmental Activities 其他发展活动10.2.4 10.2.4Clinical Development 临床开发10.2.4.1 10.2.4.1Clinical Trials Information 临床试验信息10.2.5 10.2.5Safety and Efficacy 安全性与有效性10.2.6 10.2.6Analyst View 分析师观点10.3 10.3Intismeran Autogene (MRNA-4157/V940): Moderna Therapeutics And Merck Intismeran Autogene（MRNA-4157/V940）：莫德纳治疗公司与默克公司10.4 10.4Cretostimogene Grenadenorepvec: CG Oncology 克雷托刺激基因格雷纳多诺普维克：CG肿瘤学10.5 10.5OST-HER2: Os Therapies OST-HER2：奥希替尼疗法10.6 10.6DCVAX: Northwest Biotherapeutics and Advent Bioservices DCVAX：西北生物治疗公司与Advent Bioservices10.7 10.7GLSI-100: Greenwich Lifesciences GLSI-100：格林威治生命科学公司10.8 10.8IFX-HU2.0 (IFX-2.0): Tuhura Biosciences IFX-HU2.0（IFX-2.0）：Tuhura Biosciences10.9 10.9Olvimulogene Nanivacirepvec (OLVI-VEC): Genelux Corporation Olvimulogene Nanivacirepvec（OLVI-VEC）：Genelux公司10.10 10.10SV-BR-1-GM (BRIA-IMT): Briacell Therapeutics SV-BR-1-GM（BRIA-IMT）：Briacell Therapeutics10.11 10.11S-588410: Oncotherapy Science/Shionogi S-588410：Oncotherapy Science/盐野义10.12 10.12SEVIPROTIMUT L: Transcode Therapeutics SEVIPROTIMUT L：Transcode Therapeutics10.13 10.13Oregovomab: CanariaBio 奥瑞戈莫单抗：CanariaBio10.14 10.14Aglatimagene Besadenovec (CAN-2409): Candel Therapeutics 阿格拉替马根贝萨德诺韦（CAN-2409）：Candel Therapeutics10.15 10.15Galinpepimut-S (GPS): Sellas Life Sciences Galinpepimut-S（GPS）：Sellas Life Sciences10.16 10.16BNT113: BioNtech BNT113：BioNTech10.17 10.17AST-301: Aston Sciences AST-301：阿斯顿科学公司10.18 10.18AST-201: Aston Sciences AST-201：阿斯顿科学公司List to be continued….. 列表待续……11 十一Cancer Therapeutic Vaccines: Seven Major Market Analysis 癌症治疗性疫苗：七大市场分析11.1 11.1Key Findings 主要发现11.2 11.2Cancer Vaccines Market Outlook 癌症疫苗市场前景11.3 11.3Conjoint Analysis 联合分析11.4 11.4Key Cancer Vaccines Market Forecast Assumptions 关键癌症疫苗市场预测假设11.5 11.5Total Market Size of Cancer Therapeutic Vaccines by Indications in the 7MM 七大主要市场（7MM）按适应症划分的癌症治疗性疫苗总市场规模11.6 11.6Market Size of Cancer Therapeutic Vaccines by Therapies in the 7MM 七大主要市场（7MM）中按疗法划分的癌症治疗性疫苗市场规模11.7 11.7The United States Cancer Vaccines Market 美国癌症疫苗市场11.7.1 11.7.1Total Market Size of Cancer Therapeutic Vaccines by Indications in the United States 美国按适应症划分的癌症治疗性疫苗总市场规模11.7.2 11.7.2Market Size of Cancer Therapeutic Vaccines by Therapies in the United States 美国按疗法划分的癌症治疗性疫苗市场规模11.8 11.8EU4 and the UK Cancer Vaccines Market 欧盟四国与英国癌症疫苗市场11.9 11.9Japan Cancer Vaccines Market 日本癌症疫苗市场12 12Unmet Needs 未满足的需求13 13SWOT Analysis SWOT分析14 十四KOL Views KOL观点15 十五Market Access and Reimbursement 市场准入与报销15.1 15.1The United States 美国15.2 15.2EU4 and the UK 欧盟四国与英国15.4 15.4Japan 日本15.5 15.5Summary and Comparison of Market Access and Pricing Policy Developments in 2025 2025年市场准入与定价政策发展综述及比较15.6 15.6Market Access and Reimbursement of Cancer Therapeutic Vaccines 癌症治疗性疫苗的市场准入与报销16 十六Bibliography 参考文献17 17Cancer Vaccines Market Report Methodology 癌症疫苗市场报告方法论Related Reports 相关报告Cancer Vaccines Competitive Landscape 癌症疫苗竞争格局Cancer Vaccines Competitive Landscape – 2026 癌症疫苗竞争格局 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cancer vaccine companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键癌症疫苗公司的全面洞察，包括Imvax, Transgene, BrightPath Biotherapeutics, Vaccitech, Amal Therapeutics, Enterome, Moderna, Inc., Ultimovacs ASA, OSE Immunotherapeutic, IO Biotech, PDS Biotech, LIKANGLIFE SCIENCES, ISA Pharmaceuticals, Voltron Therapeutics, Inc., RNAImmune Imvax、Transgene、BrightPath Biotherapeutics、Vaccitech、Amal Therapeutics、Enterome、Moderna, Inc.、Ultimovacs ASA、OSE Immunotherapeutic、IO Biotech、PDS Biotech、力康生命科学（LIKANG LIFE SCIENCES）、ISA Pharmaceuticals、Voltron Therapeutics, Inc.、RNAImmune, and others. ，以及其他。Prostate Cancer Market 前列腺癌市场Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 前列腺癌市场洞察、流行病学及市场预测——2036年report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including 报告深入解读了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和前列腺癌领域的主要企业，包括Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen,. 赛诺菲、阿斯利康、安斯泰来制药、拜耳、诺华、Curium、默克、奥立安制药、杨森制药、辉瑞、Exelixis、益普生制药、武田制药、AB Science、Lantheus、礼来、POINT Biopharma、Telix Pharmaceuticals、Tavanta Therapeutics、江苏恒瑞医药、康朴生物医药、Fusion Pharma、Merus、百时美施贵宝、Syntrix Pharmaceuticals、Promontory Therapeutics、Xencor、大正制药、Madison Vaccines、MacroGenics、Zenith Epigenetics、Modra Pharmaceuticals、Arvinas、来凯医药、Blue Earth Therapeutics、Oncternal Therapeutics、Essa Pharma、Clarity Pharmaceuticals、BioNTech、DualityBio、第一三共、Fortis Therapeutics、ORIC Pharmaceuticals、安进and others. 以及其他。Non-Small Cell Lung Cancer 非小细胞肺癌Market 市场Non-Small Cell Lung Cancer 非小细胞肺癌Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including 该报告深入剖析了疾病概况、历史及预测流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和包括以下在内的关键非小细胞肺癌（NSCLC）企业BeiGene 百济神州, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK, . Merus、Partner Therapeutics、强生创新制药、贝达药业、Xcovery、基石药业、百时美施贵宝、海河生物制药、大鹏药品工业株式会社、武田制药、默克雪兰诺（默克集团）、礼来公司、默沙东、再生元、赛诺菲、小野药品工业、诺华、基因泰克、罗氏、安进、中外制药、莫德纳、辉瑞、葛兰素史克and others. 以及其他。Non-muscle Invasive Bladder Cancer Market 非肌层浸润性膀胱癌市场Non-muscle Invasive Bladder Cancer 非肌层浸润性膀胱癌Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NMIBC companies including 报告深入阐述了该疾病的认知、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的NMIBC公司，包括Merck, Ferring Pharmaceuticals, ImmunityBio, CG Oncology, Pfizer, Fidia Farmaceutici, enGene, Urogen, Theralase, Johnson & Johnson, Roche, AstraZeneca, Protara Therapeutics, 默克、辉凌制药、ImmunityBio、CG Oncology、辉瑞、Fidia Farmaceutici、enGene、Urogen、Theralase、强生、罗氏、阿斯利康、Protara Therapeutics，and others. 以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。通过提供全面的端到端解决方案，助力制药公司提升业绩。通过我们的订阅制平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [email protected]+14699457679 +14699457679SOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 申请演示
